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Bronchiectasis is a chronic respiratory disease of airway dilatation, where patients typically 
suffer from respiratory infections, fatigue, sputum, cough, dyspnoea, and poor quality of 
life.(1, 2) This condition receives increased interest over the last years, with important 
developments in establishing national and international patient registries(3-5), randomized 
controlled trials of new treatments(6-8) and disease-specific health status questionnaires, 
such as the Bronchiectasis Health Questionnaire and the Quality of Life – Bronchiectasis.(9, 
10) A number of new treatment approaches have been proposed including long term 
antibiotic therapies and immune modulating drugs.(6, 7, 11, 12) 
 
Nevertheless the area of bronchiectasis care that has received the least attention during this 
period is the aspect of management that most healthcare professionals caring for 
bronchiectasis agree is the most important, airway clearance and exercise.(13, 14) The 
evidence base for respiratory physiotherapy has not advanced at the same pace as other 
aspects of bronchiectasis care.(15)  
 
To assist clinical decision making, bronchiectasis guidelines synthesise, evaluate the evidence 
and provide recommendations for clinical practice, and a number of clinical guidelines in 
bronchiectasis have been published since 2008 (Table 1). Although usually similar, guidelines 
could present some variability in their recommendations even for the same topic.(16-21) This 
is particularly the case for physiotherapy because of the limited evidence on which to base 
guideline recommendations. The purpose of this editorial is to discuss the current state of 
play worldwide with regard to airway clearance and pulmonary rehabilitation and suggest the 
need to prioritise research into these topics.  
 
Current guidelines for the clinical management of bronchiectasis are available from national 
and international organisations: the European Respiratory Society (ERS 2017), British Thoracic 
Society (BTS 2019), Thoracic Society of Australia and New Zealand (TSANZ 2015), Spanish 
Society of Pulmonology and Thoracic Surgery (SEPAR 2018), Brazilian Thoracic Association 
(BTA 2019) and Saudi Thoracic Society (STS 2017).(16-21) All guidelines refer to adults with 
bronchiectasis, whilst TSANZ and STS also include children.(16-21) Most documents are 
similar in that they are developed by multidisciplinary teams, used pre-defined PICO (patient, 
intervention, comparison, outcome) questions and used systematic literature searches to 
identify relevant evidence. To ensure integrity of the clinical guidelines, all members of the 
development panels disclosed conflict of interests, and in the ERS panel the conflicted 
members did not vote on recommendations that were of potential conflict. Moreover, some 
guidelines reported on the involvement of public or patient representatives.(16, 18, 21) 
  
Bronchiectasis guidelines discuss airway clearance techniques, muco-active treatment and 
pulmonary rehabilitation to a variable extent, along with their corresponding evidence. The 
guidelines universally recommend that patients with bronchiectasis should be taught, and 
should practice individualised airway clearance techniques and that this is best delivered by 
a respiratory physiotherapist (Table 1). The grade of relevant recommendations ranges from 
weak (ERS, BTS) to strong (SEPAR, TSANZ) and the quality of relevant evidence is rated as low 
(SEPAR, ERS, BTS, STS) to moderate (BTS, TSANZ) (Table 1).(16-21) Overall, airway clearance 
techniques show a short-term improvement in quality of life, cough-related measures and 
sputum volume expectoration compared to sham intervention and inactive control 
groups.(22, 23) A recent randomized controlled trial in 44 patients also demonstrated a 
reduction in exacerbations with twice daily airway clearance.(24) ERS, SEPAR, BTA and STS 
provide some examples of commonly practiced airway clearance techniques. BTS guideline 
recommends offering the active cycle of breathing techniques or oscillating positive 
expiratory pressure to patients, as well as considering gravity assisted positioning when this 
is not contraindicated.(18) Still, little is known about the benefits of a specific technique over 
others and data mainly come from small and short-term studies, often with a cross-over 
design.(22) BTS additionally presents a list of clinical practice advice for airway clearance 
techniques and suggests management flowcharts during a clinically stable state and an acute 
exacerbation. This guideline discusses issues such as adherence, frequency of airway 
clearance techniques and review sessions, under “good practice points”, derived from expert 
opinion.(18)  
 
Mucoactive treatments (expectorants, mucolytics, mucokinetics, and mucoregulators) are 
also discussed in all bronchiectasis guidelines.(16-21) These suggest offering long-term 
(≥3months) muco-active treatment in patients with difficulty expectorating sputum when 
standard airway clearance techniques are not adequate to control symptoms, rather than 
routinely. Most guidelines provide a strong recommendation against the use of recombinant 
human deoxyribonuclease (rhDNase) in bronchiectasis, as this is associated with higher 
exacerbation rate, more hospitalisations and a greater FEV1 decline.(25, 26) BTS provides a 
weak recommendation to use humidification with sterile water or normal saline.(18) TSANZ 
advocates to consider mucoactive treatment such as hypertonic saline and mannitol in 
patients with frequent exacerbations rather than routinely, as longitudinal randomised 
controlled trials found that these provided little benefit over isotonic saline and placebo 
treatment, respectively.(27, 28) There is therefore little clarity over when to use mucoactive 
treatments and how to define “difficulty expectorating sputum with standard airway 
clearance techniques”.  
 
Regarding pulmonary rehabilitation, small (<85 participants) and mainly short-term but well 
conducted randomised controlled trials show clinically significant improvements in exercise 
tolerance and quality of life; incremental shuttle walk distance mean change (95% confidence 
intervals, CI) 67 (52, 82) m and St George’s Respiratory Questionnaire mean change (95% CI) 
-4.65 (-6.7, -2.6) units, respectively.(26) Nevertheless a systematic review shows the evidence 
base for pulmonary rehabilitation consists of only 4 trials and 164 participants.(29) A recent 
study showed that pulmonary rehabilitation is equally effective in COPD and 
bronchiectasis.(30) There is a unanimously strong (ERS, SEPAR, TSANZ, BTS) recommendation 
for participating in pulmonary rehabilitation programmes when patients present impaired 
exercise capacity or report exercise limitation due to breathlessness. This recommendation 
was supported by moderate (TSANZ, SEPAR, STS) to high (ERS, BTS) quality of evidence.(16-
21) When defined, exercise limitation due to breathlessness is indicated by a Modified 
Medical Research Council (MMRC) Dyspnoea scale score of ≥1, which refers to the person 
that gets short of breath when hurrying on level ground or walking up a slight hill or feels 
breathless even easier than that. ERS, BTS and SEPAR consider the addition of inspiratory 
muscle training to support the maintenance of the exercise benefit, although there are no 
evidence of an additive benefit to exercise tolerance or other clinical outcomes.(17, 18, 31) 
Availability of pulmonary rehabilitation in many countries in Europe is limited due to lack of 
resources and the lack of evidence.  
 
Guidelines support airway clearance and the use of mucoactive treatment based on low to 
moderate level of evidence, which indicates that further research could change our 
confidence in the estimated effect. On the other hand, pulmonary rehabilitation is supported 
by moderate to high quality of evidence, providing greater confidence on the effect of this 
treatment. Patients seem to accept and value airway clearance techniques and pulmonary 
rehabilitation but long term compliance with them is unknown.(32) Moreover, airway 
clearance and pulmonary rehabilitation bronchiectasis recommendations largely rely on 
studies during a clinically stable stage. Thus, clinically, we are mainly called to extrapolate 
these results to disease exacerbations or assume that clinical outcomes will resemble those 
of other respiratory conditions; this could be misleading.  
 
The evidence base for bronchiectasis therapy is evolving, but whereas several thousand 
patients have now been enrolled into trials of high cost therapies such as inhaled antibiotics 
or inhaled mucoactive drugs, trials that have been largely unsuccessful, there have been no 
large trials of airway clearance and pulmonary rehabilitation.(6, 8, 33) A search of 
Clinicaltrials.gov and other trial databases identified no trials with >100 participants of these 
two interventions. The UK CLEAR trial of hypertonic saline and carbocisteine is an encouraging 
development that will recruit 380 patients (ISRCTN89040295). The absence of standardised, 
quality assured airway clearance across centres participating in pharmacotherapy trials has 
been cited as one potential reason for their heterogeneous results.(34, 35)   
 
Preliminary data show that access to airway clearance techniques and pulmonary 
rehabilitation is highly variable in patients with bronchiectasis across Europe.(35, 36) 
Bronchiectasis audits have also shown that implementation of the guidelines can be limited 
and even adherence to national standards on patient care is variable.(37-40) In the era of 
evidence-based medicine, evidence for what is considered usual care and a core part of 
bronchiectasis management is paramount for the implementation of the best available 
treatment. Once high-quality studies, evidence and strong clinical guidelines are available, 
our aim could focus on the local implementation. Still, it seems a long way to that, and the 
question remains “how could we address these outstanding uncertainties as a community”?  
 
We issue a call to action, urging researchers, clinicians, funding bodies and the European 
Respiratory Society to prioritise airway clearance and pulmonary rehabilitation. Large 
randomized studies of these interventions are feasible, particularly with the availability of 
large registries and recently developed standardised endpoints.(41)  
 
Clinical guidelines since 2008 have underlined the need for high quality evidence to support 
these therapies that bronchiectasis patients are recommended on a daily basis. Questions 
that remain unresolved include the role of airway clearance in stable disease and 
exacerbation, the optimum method of clearance, duration and frequency for improving long 
term and clinical important outcomes in various disease severities. We need more data about 
the impact of airway clearance and pulmonary rehabilitation treatments in numerous areas, 
particularly exacerbations and hospitalisations; the role of physiotherapists in individualised 
action plans and home intravenous antibiotics; education in pulmonary rehabilitation; self-
management; treatment compliance; and links between primary and secondary healthcare.  
 
Airway clearance is largely individualised, and this remains a profound research challenge. It 
is acknowledged that large clinical trials including a comparator arm of no physiotherapy 
present ethical and logistical challenges as airway clearance is a standard part of care, and 
blinding is challenging. Innovative trial designs including cluster randomized approaches, 
active comparator studies or step-wedge implementation trials are alternatives which can 
overcome any barriers.  
 
Great steps forward have been taken in changing bronchiectasis from an “orphan disease” 
but respiratory physiotherapy remains an orphan topic even in this “age of bronchiectasis”. 
This has to change, for the benefit of all our patients.  
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Year Databases of review Last date of search Level of evidence appraisal system 
ERS 2017 PubMed -MEDLINE-, Cochrane Central Register of Controlled 
Trials (CENTRAL), Cochrane Library 
Dec-16 GRADE 
BTS 2010, 2019 PubMed -MEDLINE-, EMBASE, Cochrane Library, Database of 
Abstracts of Reviews of Effects (DARE), Health Technology 
Assessment (HTA), NHS Economic Evaluation Database (NHS EED) 
Jun-16 SIGN 
SEPAR 2008, 2018 PubMed -MEDLINE-, EMBASE, Cochrane Library, Database of 
Abstracts of Reviews of Effects (DARE), Health Technology 
Assessment (HTA) 
Feb-17 GRADE 
TSANZ* 2008, 2010, 2015 PubMed, Cochrane Central Library Oct-13 Revised GRADE 
BTA** 2019 NR NR NR 
STS* 2017 Not reported Not reported Costume-made appraising  
(A, B, C, D) 
 
Current guidelines are in bold. 
*: indicates that the guidelines include recommendations for children 
**This guideline used a narrative literature review. 
NR: none reported.  
Costume-made appraising system: A indicating high quality of evidence from RCTs and meta-analysis to D panel consensus  
Abbreviations: 
ERS: European Respiratory Society, BTS: British Thoracic Society, SEPAR: Spanish Thoracic Society, TSANZ: Thoracic Society of Australia and 
New Zealand, BTA: Brazilian Thoracic Association, STS: Saudi Thoracic Society, GRADE: Grading of Recommendations Assessment, 
Development and Evaluation, SIGN: Scottish Intercollegiate Guidelines Network grading system. 
 
 
Table 2. Overview of respiratory physiotherapy recommendations in current clinical guidelines.  
Guidelines  Recommendation Grade of 
recommendation 
Quality of evidence 
Airway clearance techniques 
ERS 2017 • teach ACT by respiratory physiotherapist 
• perform ACT once or twice daily in chronic 
productive cough or difficulty to 
expectorate 
weak low 
BTS 2019 • teach ACT to perform  D 3 to 1- 
• offer ACBT or o-PEP  
• consider gravity assisted positioning where 
not contraindicated to enhance 
effectiveness of ACT 
D 1- 
SEPAR 2018 • ACTs are safe 
• in stable bronchiectasis with productive 
cough (hypersecretion or frequent 
exacerbations) 
strong low 
TSANZ 2015 • perform ACT  
• get respiratory physiotherapist’s advice 
• individualise ACT 
strong moderate 
BTA 2019 • teach and apply ACT to all patients with 
chronic production of secretions and/or (CT 
scan) signs of mucus plugging 
NR NR 
STS 2017 • lack of data about role of ACT in acute 
exacerbation, it may be used if no 
contraindications  
• consider patient’s preference and 
adherence to treatment  
• teach patient or caregiver and encourage 
use of ACT and appropriate device 
NR D  
• ACT is safe and may improve sputum 
expectoration, lung function and quality of 
life in stable bronchiectasis 
NR C 
Mucoactive treatment 
ERS 2017 • long-term mucoactive treatment in 
difficulty to expectorate sputum and poor 
quality of life, and where ACT cannot 
control symptoms 
weak low 
• rhDNase is contraindicated strong moderate 
BTS 2019 • consider use of humidification with sterile 
water or normal saline 
D 3 to 1+ 
• do not routinely use rhDNSase A 1+ 
SEPAR 2018 • insufficient evidence to recommend routine 
use of mucolytics 
strong low 
• hypertonic substances recommended in 
expectoration >10 mL per day despite other 
treatment 
strong moderate 
TSANZ 2015 • mucoactive agents are not routinely 
recommended 
• consider trial in frequent exacerbations 
weak moderate 
• rhDNase is contraindicated strong high 
BTA 2019 • consider using hypertonic saline in 
persistent secretions despite other 
measures 
NR NR 
• supervise first administration of hypertonic 
saline to assess adverse events, which can 
be prevented or minimized by prior 
administration of short-acting 
bronchodilator 
NR NR 
• insufficient evidence to recommend routine 
use of mucolytics 
• DNase is contraindicated 
NR NR 
STS 2017 • nebulised saline or mannitol may increase 
ease of sputum expectoration and decrease 
its viscosity 
NR B  
• be aware of airway hyper-responsiveness, 
as it occurs in approximately 12% of 
patients 
NR D 
• rhDNase is not recommended as potentially 
harmful 
NR A  
Pulmonary rehabilitation 
ERS 2017 • participate in PR  
• tailor to patient’s symptoms, physical 
capability and disease characteristics 
strong high 
BTS 2019 • offer PR to those functionally limited by 
shortness of breath (mMRC ≥1)  
• consider the use of inspiratory muscle 
training in conjunction to PR to enhance 
maintenance of the training effect  
B  1- to 1+ 
SEPAR 2018 • participate in PR 
• stable patients with mMRC dyspnoea scale 
>1 
strong moderate 
TSANZ 2015 • participate in PR when exercise limitation strong moderate 
BTA 2019 • refer to regular exercise and PR program, if 
available 
• in clinically stable patients with chronic 
hypercapnic respiratory failure, non-
invasive mechanical ventilation by BiPAP 
should be used as an adjuvant to 
cardiopulmonary rehabilitation 
NR NR 
STS 2017 • PR recommended as potential 




Explaining BTS grade of recommendation appraisal system: A: a systematic review of RCTs 
or a body of evidence consisting principally of studies rated as 1+ directly applicable to the 
target population and demonstrating overall consistency of results, B: a body of evidence 
including studies rated as 2++ directly applicable to the target population and 
demonstrating overall consistency of results or extrapolated evidence from studies rated as 
1++ or 1+, D:  evidence of level 3 or expert opinion or extrapolated evidence from studies 
rated as 2+.  
Explaining BTS level of evidence appraisal system: 1+: well conducted meta-analyses, 
systematic reviews of RCTs, or RCTs with low risk of bias, 1-: meta-analyses, systematic 
reviews of RCTs or RCTs with high risk of bias, 3: non analytic studies, for example, case 
reports, case series. 
Explaining STS system: A: RCTs with rich body of data or meta-analysis from RCTs, B: RCTs 
with a limited body of data or meta-analysis from non-RCTs, C: non-randomised trials and 
observational studies, D: panel consensus. 
Abbreviations: 
ERS: European Respiratory Society, BTS: British Thoracic Society, SEPAR: Spanish Thoracic 
Society, TSANZ: Thoracic Society of Australia and New Zealand, BTA: Brazilian Thoracic 
Association, STS: Saudi Thoracic Society, 
RCT: randomised control trial, ACT: airway clearance techniques, o-PEP: oscillatory positive 
expiratory pressure, BiPAP: bilevel positive airway pressure. 
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